• Chat
  • Dashboard
  • Daily Briefing
  • Discover
    • Feedback
    • Sign In
    Sign InSign Up

    Vir Biotech Catapults On Its $1.71 Billion Deal With Astellas - Investor's Business Daily

    AI Summary1 min read

    TL;DR

    Vir Biotechnology's stock surges after announcing a $1.71 billion collaboration with Astellas to develop VIR-5500, a prostate cancer drug, including a $240 million upfront payment.

    Tags

    Vir BiotechnologyAstellasprostate cancerbiotech dealVIR-5500
    1. Vir Biotech Catapults On Its $1.71 Billion Deal With Astellas  Investor's Business Daily
    2. Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer  PR Newswire
    3. Astellas pays $240M cash for Vir’s prostate cancer drug  Endpoints News
    4. This Small-Cap Biotech Stock Is Soaring 29%. There’s Excitement Over Its Prostate Cancer Drug.  Barron's
    5. ‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific  Fierce Biotech

    Tuesday, February 24, 2026 3:05 PM

    Visit Website
    website-logo

    Top stories - Google News

    Google News

    channel icon
    Related Articles

    Travel ban lifted but motorists still urged to stay off roads as dig out continues - WCVB

    Feb 24, 2026

    Hungary blocks Europe’s aid for Ukraine on war’s fourth anniversary - The Washington Post

    Feb 24, 2026

    Investors Are Dumping Software Stocks and Earnings Won’t Stop It - Yahoo Finance

    Feb 24, 2026

    Google Messages more widely rolling out circular read receipts redesign - 9to5Google

    Feb 24, 2026
    xgithub
    logo

    Copyright © 2022-2026 - Aetos.AI